Oxiracetam cas: 62613-82-5

CAS NO: 62613-82-5
Oxiracetam
Description Review
Description

Oxiracetam CAS: 62613-82-5 is a nootropic compound that is a member of the racetam family of compounds. It was first synthesized in the 1970s and has been studied for its potential cognitive-enhancing effects.

Chemical Name:

Oxiracetam is also known as (RS)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide.

Molecular Formula:

The molecular formula of Oxiracetam is C6H10N2O3.

Formula Weight:

The formula weight of Oxiracetam is 158.16 g/mol.

CAS No:

The CAS number of Oxiracetam is 62613-82-5.

Top Ten Keywords from Google and Synonyms:

  1. Cognitive Enhancer
  2. Memory Booster
  3. Focus Improver
  4. Intelligence Agent
  5. Smart Drug
  6. Learning Aid
  7. Racetam Compound
  8. Nootropic Supplement
  9. Mood Stabilizer
  10. Brain Health Supplement

Health Benefits of Oxiracetam:

Oxiracetam is believed to provide various health benefits due to its potential cognitive-enhancing effects. Some of the potential benefits of Oxiracetam include:

  1. Improved Memory: Oxiracetam may improve memory and learning ability by increasing the activity of neurotransmitters such as acetylcholine and glutamate.

  2. Increased Focus: Oxiracetam may increase focus and attention by enhancing the activity of dopamine and norepinephrine in the brain.

  3. Mood Stabilization: Oxiracetam may stabilize mood and reduce anxiety by modulating the activity of GABA receptors in the brain.

Potential Effects:

Oxiracetam can produce a range of effects depending on the dosage and individual response. Some of the potential effects of Oxiracetam include:

  1. Improved Memory: Oxiracetam may improve memory and learning ability by increasing the activity of neurotransmitters such as acetylcholine and glutamate.

  2. Increased Focus: Oxiracetam may increase focus and attention by enhancing the activity of dopamine and norepinephrine in the brain.

  3. Mood Stabilization: Oxiracetam may stabilize mood and reduce anxiety by modulating the activity of GABA receptors in the brain.

Product Mechanism:

Oxiracetam works by modulating the activity of various neurotransmitters in the brain, including acetylcholine, glutamate, dopamine, norepinephrine, and GABA. By enhancing the activity of these neurotransmitters, Oxiracetam can improve cognitive function, increase focus, and stabilize mood.

Safety:

Oxiracetam can be safe when used appropriately and under medical supervision. However, it can cause adverse effects if misused or abused. Some of the potential side effects of Oxiracetam include:

  1. Headaches: Oxiracetam may cause headaches in some individuals.

  2. Insomnia: Oxiracetam may cause insomnia in some individuals.

  3. Nausea: Oxiracetam may cause nausea or gastrointestinal disturbances in some individuals.

Dosing Information:

The appropriate dose of Oxiracetam depends on several factors such as age, weight, and health status. It is essential to follow dosing instructions carefully and not exceed the recommended dose.

Conclusion:

Oxiracetam is a member of the racetam family of compounds that has been studied for its potential cognitive-enhancing effects. It works by modulating the activity of various neurotransmitters in the brain, including acetylcholine, glutamate, dopamine, norepinephrine, and GABA. While Oxiracetam may provide some health benefits, it should only be used under medical supervision and with caution due to its potential side effects


Oxiracetam is a racetam that differs structurally from piracetam by a single hydroxyl group. It is also used for nootropic purposes, such as improving student learning or preventing cognitive decline. It, like all other racetams, is a synthetic molecule that does not exist in food or nature.

What else is Oxiracetam known as?
Note that Oxiracetam is also known as:4-hydroxy-2-oxo-pyrrolidinoacetamide
ISF-2522
Oxiracetam should not be confused with:Aniracetam or Piracetam
Oxiracetam has been used in organic brain syndromes and senile dementia for its nootropic effects


Oxiracetam (developmental code name ISF 2522) is a racetam-family nootropic and a very mild stimulant. Several studies indicate that the substance is safe even when consumed in high doses for an extended period of time. The mechanism of action of the racetam drug family, on the other hand, is still under investigation. In the United States, the Food and Drug Administration has not approved oxiracetam for any medical use.

Oxiracetam has a bioavailability of 56-82% from the gastrointestinal tract. Peak serum levels are reached one to three hours after a single 800 mg or 2000 mg oral dose, with maximum serum concentrations ranging from 19 to 31 g/ml at these doses.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code